Form 4 for RAPP Rapport Therapeutics, Inc.

Accepted 2026-07-15 16:15:03 ET · period of report 2026-07-14 · accession 0001193125-26-304786 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MT	2026-07-15 16:15	2026-07-14	RAPP	Ceesay Abraham	CEO, Dir	S - Sale	$40.00	-8,210	539.8K	-1%	-$328.4K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-07-14	S	D	5,481	$39.72	542,546	D	—	—	(F1) These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.36 to $40.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
2	Common	Common Stock	2026-07-14	S	D	2,729	$40.57	539,817	D	—	—	(F1) These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.37 to $40.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.